Management of Symptomatic Sinus Bradycardia

Introduction

Symptomatic sinus bradycardia is a condition that requires prompt management to prevent complications, with the American College of Cardiology and the American Heart Association providing guidelines for its treatment 1, 2, 3

The American College of Cardiology recommends atropine 0.5-1 mg IV as the first-line treatment for symptomatic sinus bradycardia, which may be repeated every 3-5 minutes to a maximum dose of 3 mg, with the goal of achieving a minimally effective heart rate of approximately 60 bpm 1, 2, 3
The American Heart Association also recommends atropine 0.5-1 mg IV for symptomatic bradycardia, which may be repeated to a maximum of 3 mg, and if bradycardia is unresponsive to atropine, suggests initiating transcutaneous pacing (TCP) and beginning IV infusion of β-adrenergic agonists (dopamine or epinephrine) 4, 1

The American Heart Association suggests dopamine as a second-line treatment, administered as a 5-20 mcg/kg/min IV infusion, starting at 5 mcg/kg/min and increasing by 5 mcg/kg/min every 2 minutes, with caution against doses greater than 20 mcg/kg/min due to the risk of vasoconstriction or arrhythmias 1, 3
Second-line treatments for symptomatic bradycardia include dopamine, epinephrine, or isoproterenol, or IV infusion of β-adrenergic agonists or transcutaneous pacing, as recommended by the American College of Cardiology 2, 5

The American College of Cardiology recommends identifying and treating reversible causes of sinus bradycardia, including medications, acute myocardial ischemia/infarction, electrolyte abnormalities, hypothyroidism, increased vagal tone, hypothermia, hypoxemia, hypercarbia, and acidosis 1, 2
The American College of Cardiology advises against using atropine in heart transplant patients, as it is ineffective due to cardiac denervation (Class III: Harm) 1, 2
The American College of Cardiology states that atropine is ineffective and should not be used for infranodal AV block, including type II second-degree AV block or third-degree AV block with wide QRS 6, 7
The American College of Cardiology recommends no treatment for asymptomatic bradycardia (Class III) 6, 7

The American College of Cardiology indicates that permanent pacing is recommended for symptomatic bradycardia that cannot be managed medically or when bradycardia-induced VT is recurrent, and for patients with both bradycardia and risk of ventricular arrhythmias, recommends evaluating for ICD therapy before implantation 8, 1
Dual chamber pacing is preferred over single chamber ventricular pacing when atrioventricular conduction is intact, as recommended by the American Heart Association, and permanent pacing may be considered if beta blocker therapy is essential and bradycardia worsens, as recommended by the American College of Cardiology 1, 2

Beta blockers should be used with caution in patients with bradycardia, starting at low doses and titrating slowly, and discontinued if bradycardia worsens or becomes symptomatic, as advised by the American College of Cardiology, and should be started at very low doses and titrated gradually to minimize the risk of bradycardia, as recommended by the European Heart Journal and the American Heart Association 9, 10, 11, 9
Diltiazem or verapamil may be used for rate control in patients with atrial fibrillation, but with close monitoring for rate control and risk of bradycardia, as recommended by the American Heart Association 12

Continuous cardiac monitoring is essential during the entire period of management for bradycardia-induced VT, as recommended by the American Heart Association, and initial workup for bradycardia should include a 12-lead ECG, vital signs assessment, focused history, and laboratory tests based on clinical suspicion, as recommended by the American College of Cardiology 13, 3, 5, 1
Long-term ambulatory monitoring with an implantable cardiac monitor may be considered for patients with infrequent symptoms, as recommended by the American Heart Association 8, 1

High vagal tone, especially during sleep, is a physiological factor that can contribute to sinus bradycardia, as noted by the American College of Cardiology, and bradycardia can cause clinical manifestations such as syncope, presyncope, dizziness, heart failure symptoms, or confusional states, according to the American College of Cardiology/American Heart Association guidelines 2

Permanent pacemaker presence does not contraindicate pregnancy, as stated by the European Heart Journal, and spontaneous vaginal delivery is preferred if the cardiac condition is stable, and assisted vaginal delivery should be considered to shorten the second stage of labor, as recommended by the European Journal of Heart Failure 14, 15

Urgent revascularization is indicated for acute ischemia, as recommended by the European Society of Cardiology, and the American Heart Association recommends IV amiodarone and β-blockers to reduce recurrence of polymorphic VT without long QT, and for polymorphic VT with long QT (torsades de pointes), suggests IV magnesium and pacing at rates 80-110 bpm, and correcting any electrolyte abnormalities, particularly potassium and magnesium 16, 5